Plant-based production and characterization of a promising Fc-fusion protein against microgravity-induced bone density loss
Open Access
- 12 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 962292
Abstract
Microgravity-induced bone loss is a main obstacle for long term space missions as it is difficult to maintain bone mass when loading stimuli is reduced. With a typical bone mineral density loss of 1.5% per month of microgravity exposure, the chances for osteoporosis and fractures may endanger astronauts’ health. Parathyroid Hormone or PTH (1–34) is an FDA approved treatment for osteoporosis, and may reverse microgravity-induced bone loss. However, PTH proteins requires refrigeration, daily subcutaneous injection, and have a short shelf-life, limiting its use in a resource-limited environment, like space. In this study, PTH was produced in an Fc-fusion form via transient expression in plants, to improve the circulatory half-life which reduces dosing frequency and to simplify purification if needed. Plant-based expression is well-suited for space medicine application given its low resource consumption and short expression timeline. The PTH-Fc accumulation profile in plant was established with a peak expression on day 5 post infiltration of 373 ± 59 mg/kg leaf fresh weight. Once the PTH-Fc was purified, the amino acid sequence and the binding affinity to its target, PTH 1 receptor (PTH1R), was determined utilizing biolayer interferometry (BLI). The binding affinity between PTH-Fc and PTH1R was 2.30 × 10−6 M, similar to the affinity between PTH (1–34) and PTH1R (2.31 × 10−6 M). Its function was also confirmed in a cell-based receptor stimulation assay, where PTH-Fc was able to stimulate the PTH1R producing cyclic adenosine monophosphate (cAMP) with an EC50 of (8.54 ± 0.12) x 10−9 M, comparable to the EC50 from the PTH (1–34) of 1.49 × 10−8 M. These results suggest that plant recombinant PTH-Fc exhibits a similar binding affinity and potency in a PTH1R activation assay compared to PTH. Furthermore, it can be produced rapidly at high levels with minimal resources and reagents, making it ideal for production in low resource environments such as space.Keywords
Funding Information
- National Aeronautics and Space Administration (NNX17AJ31G NNX16AO69A)
This publication has 17 references indexed in Scilit:
- PROSPER: An Integrated Feature-Based Tool for Predicting Protease Substrate Cleavage SitesPLOS ONE, 2012
- Aging and bone loss: new insights for the clinicianTherapeutic Advances in Musculoskeletal Disease, 2011
- Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plantsHuman Vaccines, 2011
- Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Extremely High-Level and Rapid Transient Protein Production in Plants without the Use of Viral ReplicationPlant Physiology, 2008
- Preventing unintended proteolysis in plant protein biofactoriesPlant Biotechnology Journal, 2008
- Foliar extracts from transgenic tomato plants expressing the structural polyprotein, P1-2A, and protease, 3C, from foot-and-mouth disease virus elicit a protective response in guinea pigsVeterinary Immunology and Immunopathology, 2008
- Infrequent Delivery of a Long-Acting PTH-Fc Fusion Protein Has Potent Anabolic Effects on Cortical and Cancellous BoneJournal of Bone and Mineral Research, 2007
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- BONE DEMINERALIZATION OF FOOT AND HAND OF GEMINI-TITAN IV, V AND VII ASTRONATUS DURING ORBITAL FLIGHTAmerican Journal of Roentgenology, 1967